C4 therapeutics reports recent business highlights and full year 2020 financial results

– phase 1/2 trial for lead candidate cft7455, a monodac™ degrader targeting ikzf1/3 for the treatment of hematologic malignancies, on track for 1h 2021 initiation following fda clearance of investigational new drug (ind) –

CCCC Ratings Summary

CCCC Quant Ranking